Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
about
Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron diseaseRecombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron diseaseSubcutaneous IGF-1 is not beneficial in 2-year ALS trialIntrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patientsEmerging drugs for sarcopenia: age-related muscle wastingSurvival activity of troglitazone in rat motoneurones.Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors.Neurotrophic factor therapy--prospects and problems.Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.Therapeutic developments in the treatment of amyotrophic lateral sclerosis.Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neuronsImpaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients.Extracellular vimentin interacts with insulin-like growth factor 1 receptor to promote axonal growth.IGF-1 restores visual cortex plasticity in adult life by reducing local GABA levelsThe lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS.Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALSNeurotrophic factors and amyotrophic lateral sclerosis.The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives.Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.αCAR IGF-1 vector targeting of motor neurons ameliorates disease progression in ALS mice.Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3).Neurotrophic modulation of motor neuron development.Focal application of neutralizing antibodies to soluble neurotrophic factors reduces collateral axonal branching after peripheral nerve lesion.Hair cell generation in vestibular sensory receptor epithelia.IGF-I deficient mice show reduced peripheral nerve conduction velocities and decreased axonal diameters and respond to exogenous IGF-I treatment.Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis.Potentiation of quantal secretion by insulin-like growth factor-1 at developing motoneurons in Xenopus cell culture.Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity.Could IGF-I levels play a neuroprotective role in patients with large vestibular schwannomas?Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS.Circulating biomarkers in extremely preterm infants associated with ultrasound indicators of brain damage.rhIGF-I administration in humans: differential metabolic effects of bolus vs. continuous subcutaneous delivery.Down regulation of trophic factors in neonatal rat spinal cord after administration of cerebrospinal fluid from sporadic amyotrophic lateral sclerosis patients.
P2860
Q24197515-A3A882A9-7F39-4F78-BB6C-EB931BF0BCE4Q24242947-5D98A1FB-F646-42FE-B873-FC0249EF54ABQ24651555-C06B1599-2338-4994-8C60-A944EA445EECQ28279918-EB5E7372-B02E-4FC3-9D20-BE7268110220Q28295716-9430AD21-8983-4CB4-82F6-15041B823D3FQ32034710-A808D278-DB8B-4B29-B765-5D6B1687D7E7Q33989037-25D9D4A3-63A0-41D6-970A-5D617B97A42EQ34270998-74277253-0B5E-4272-927C-376B8113DFF8Q34757963-88A7F355-9074-4D46-8D27-140CA0401C6BQ34974850-4FDEF9E7-7D49-4E52-BE36-7E28F082A046Q35728813-BAB48AB4-FAD0-4FEC-B81B-C426DD139BA5Q35837412-957BB9EF-BC34-441D-BFF9-4654FC7E45A6Q35847939-2235280C-8964-48B0-A331-27418E5A73F2Q36031801-8232944C-0D73-47A7-BFE7-A3548BD7B7C0Q36094664-EB042F94-64F0-4767-A8CC-F7F68EAE7DB3Q36491424-05DCD4FB-D4F2-46A1-9586-92D08834D3FFQ36565607-A470B259-060E-47F7-BC75-C9CD83DBAEE1Q36684355-AE3720B5-2E94-414E-9E61-C6AAC89D0804Q36726598-B006BB16-3636-4809-A27F-1AD6038B2333Q37257924-83496248-B6C3-4119-9439-D8B05B39C4B0Q37307491-7C3245FB-C720-4E83-B596-E37CE30FF7A1Q37381231-DB330CD9-7F28-4C20-B8A4-DE2F2FFEB561Q37393565-4132D98F-BAA4-4F99-A171-10D04D436BDEQ40734110-3CDBF9B6-F71B-4AD8-A53D-859FE65AE7B7Q41023871-90D54F20-C343-455E-8E8C-B8A36E59DDF3Q41647567-F9E244E5-F21A-43FA-86BE-405D66F73E0FQ42285046-6B33D617-54BA-4178-946A-857B4ED8B562Q44599989-90C4C307-12DE-4DA6-87C9-920F240ED10FQ45881053-875E4497-E67A-441C-B869-240600C2B877Q47705965-695B7B1A-1B0C-4917-9064-96E725FAC7BEQ47776083-FA3D64FA-A9C2-42E0-A329-DD10AA3E6AFEQ50074937-C292527C-7E9C-4FB9-8620-818D2087779DQ51575789-00C45D0C-478E-4AEE-A04F-AA4238416E62Q51829226-92E30AA0-6059-4200-BD67-EABCB1C697A9
P2860
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@ast
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@en
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@nl
type
label
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@ast
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@en
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@nl
prefLabel
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@ast
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@en
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@nl
P2093
P356
P1476
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
@en
P2093
Contreras PC
Oppenheim RW
P356
10.1006/EXNR.1993.1177
P407
P577
1993-11-01T00:00:00Z